FDA
-
-
-
-
-
-
-
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
-
-
-
-
-
-
-
Ryoncil® Net Revenues Increase for the Quarter to US$30M
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
-
-
-
-
-
-
-
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
-
-
-
-
-
-
-
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
-
-
-
-
-
-
-
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
-
322,282 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

